A colorimetric CMOS-based platform for rapid total serum cholesterol quantification

Article English OPEN
Al-Rawhani, Mohammed A. ; Cheah, Boon Chong ; MacDonald, Alasdair Iain ; Martin, Christopher ; Hu, Chunxiao ; Beeley, James ; Gouveia, Luiz Carlos ; Grant, James P. ; Campbell, Gordon ; Barrett, Michael P. ; Cumming, David R.S. (2017)

Elevated cholesterol levels are associated with a greater risk of developing cardiovascular disease and other illnesses, making it a prime candidate for detection on a disposable biosensor for rapid point of care diagnostics. One of the methods to quantify cholesterol levels in human blood serum uses an optically mediated enzyme assay and a bench top spectrophotometer. The bulkiness and power hungry nature of the equipment limits its usage to laboratories. Here, we present a new disposable sensing platform that is based on a complementary metal oxide semiconductor process for total cholesterol quantification in pure blood serum. The platform that we implemented comprises readily mass-manufacturable components that exploit colorimetric changes of cholesterol oxidase and cholesterol esterase reactions. We have shown that our quantification results are comparable to that obtained by a bench top spectrophotometer. Using the implemented device, we have measured cholesterol concentration in human blood serum as low as 29 μM with a limit of detection at 13 μM, which is approximately 400 times lower than average physiological range, implying that our device also has the potential to be used for applications that require greater sensitivity.
  • References (28)
    28 references, page 1 of 3

    [1] P. Yager, G. J. Domingo, and J. Gerdes, “Point-of-care diagnostics for global health,” Annu. Rev. Biomed. Eng., vol. 10, pp. 107-144, Jan. 2008.

    [2] I. V. Jani and T. F. Peter, “How point-of-care testing could drive innovation in global health,” New England J. Med., vol. 368, no. 24, pp. 2319-2324, Jun. 2013.

    [3] D. A. Giljohann and C. A. Mirkin, “Drivers of biodiagnostic development,” Nature, vol. 462, pp. 461-464, Nov. 2009.

    [4] A. P. F. Turner, “Biosensors: Sense and sensibility,” Chem. Soc. Rev., vol. 42, no. 8, pp. 3184-3196, Apr. 2013.

    [5] C. D. Chin et al., “Microfluidics-based diagnostics of infectious diseases in the developing world,” Nature Med., vol. 17, no. 8, pp. 1015-1019, Aug. 2011.

    [6] X. Zhang, H. Ju, and J. Wang, Electrochemical Sensors, Biosensors and Their Biomedical Applications. San Diego, CA, USA: Academic, 2008, pp. 57-67.

    [7] M. S. Monteiro, M. Carvalho, M. L. Bastos, and P. G. De Pinho, “Metabolomics analysis for biomarker discovery: Advances and challenges,” Current Med. Chem., vol. 20, no. 2, pp. 257-271, Jan. 2013.

    [8] A. Nordström and R. Lewensohn, “Metabolomics: Moving to the clinic,” J. Neuroimmune Pharmacol., vol. 5, no. 1, pp. 4-17, Mar. 2010.

    [9] E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults findings from the third national health and nutrition examination survey,” J. Amer. Med. Assoc., vol. 287, no. 3, pp. 356-359, 2002.

    [10] Scandinavian Simvastatin Survival Study Group, “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S),” Lancet, vol. 344, no. 8934, pp. 1383-1389, Nov. 1994.

  • Metrics
    No metrics available
Share - Bookmark